L. González

发表

A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern

A. Sette, D. Weiskopf, P. González, 2022, mBio.

Interim Report: Safety And Immunogenicity Of An Inactivated Vaccine Against Sars-Cov-2 In Healthy Chilean Adults In A Phase 3 Clinical Trial

A. Sette, D. Weiskopf, P. González, 2021, medRxiv.

Identification of biomarkers for disease severity in nasopharyngeal secretions of infants with upper or lower respiratory tract viral infections

A. Kalergis, S. Bueno, C. Riedel, 2022, Clinical and experimental immunology.

Differences in the immune response elicited by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial

A. Sette, D. Weiskopf, D. Goldblatt, 2022, eLife.

Differential immune response induced by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial

D. Weiskopf, A. Grifoni, R. Soto-Rifo, 2022, medRxiv.

A booster dose of an inactivated vaccine increases neutralizing antibodies and T cell responses against SARS-CoV-2

A. Sette, D. Weiskopf, P. González, 2021, medRxiv.

Evaluation of monoclonal antibodies that detect conserved proteins from Respiratory Syncytial Virus, Metapneumovirus and Adenovirus in human samples.

S. Bueno, C. Riedel, A. A. Beckhaus, 2018, Journal of virological methods.

Characterization of the Anti-Inflammatory Capacity of IL-10-Producing Neutrophils in Response to Streptococcus pneumoniae Infection

P. González, J. Soto, A. Kalergis, 2021, Frontiers in Immunology.

Safety and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine in a Subgroup of Healthy Adults in Chile.

A. Sette, D. Weiskopf, P. González, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine

P. González, Weining Meng, N. Gálvez, 2021, Frontiers in Immunology.

Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine

A. Sette, D. Weiskopf, P. González, 2021, Frontiers in Immunology.

Cytokines in the Respiratory Airway as Biomarkers of Severity and Prognosis for Respiratory Syncytial Virus Infection: An Update

P. González, S. Bueno, C. Riedel, 2019, Front. Immunol..

Interleukin-10 Produced by Myeloid-Derived Suppressor Cells Provides Protection to Carbapenem-Resistant Klebsiella pneumoniae Sequence Type 258 by Enhancing Its Clearance in the Airways

A. Prince, S. Bueno, Isidora Suazo, 2019, Infection and Immunity.

L-Arginine Enhances Intracellular Killing of Carbapenem-Resistant Klebsiella pneumoniae ST258 by Murine Neutrophils

S. Bueno, A. Piña-Iturbe, B. M. Schultz, 2020, Frontiers in Cellular and Infection Microbiology.

A booster dose of an inactivated SARS-CoV-2 vaccine increases neutralizing antibodies and T cells that recognize Delta and Omicron variants of concern.

A. Sette, D. Weiskopf, P. González, 2022, medRxiv : the preprint server for health sciences.